Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice

Journal of Neuroscience

Volumn 26, Issue 52, 2006, Pages 13548-13555

  Xiao, Danqing ^a   Bastia, Elena ^a   Xu, Yue Hang ^a   Benn, Caroline L ^a   Cha, Jang Ho J ^a   Peterson, Tracy S ^c   Chen, Jiang Fan ^b   Schwarzschild, Michael A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

6 hydroxydopamine; A2A receptor antagonist; Basal ganglia; Conditional A 2A knock out; KW 6002; Parkinson's disease

Indexed keywords

1,3 DIETHYL 8 (3,4 DIMETHOXYSTYRYL) 7 METHYL 3,7 DIHYDRO 1H PURINE 2,6 DIONE]; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; LEVODOPA; UNCLASSIFIED DRUG; ISTRADEFYLLINE; OXIDOPAMINE; PURINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CIRCLING BEHAVIOR; CONTROLLED STUDY; DYSKINESIA; FOREBRAIN; INVOLUNTARY MOVEMENT; MALE; MOUSE; NERVE CELL PLASTICITY; NERVE POTENTIAL; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; SENSITIZATION; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; MOUSE MUTANT; PHYSIOLOGY;

ANIMALS; DYSKINESIA, DRUG-INDUCED; LEVODOPA; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OXIDOPAMINE; PARKINSONIAN DISORDERS; PROSENCEPHALON; PURINES; RECEPTOR, ADENOSINE A2A;

EID: 33845899095     PISSN: 02706474     EISSN: 02706474     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.3554-06.2006     Document Type: Article

References (51)

1. 2A receptor antagonist treatment of Parkinson's disease. Neurology 61:293-296.
2. Bastia E, Xu YH, Scibelli AC, Day YJ, Linden J, Chen JF, Schwarzschild MA (2005) Acrucial role for forebrain adenosine A(2A) receptors in amphetamine sensitization. Neuropsychopharmacology 30:891-900.
3. Bedard PJ, Blanchet PJ, Levesque D, Soghomonian JJ, Grondin R, Morissette M, Goulet M, Calon F, Falardeau P, Gomez-Mancilla B, Doucet JP, Robertson GS, DiPaolo T (1999) Pathophysiology of L-DOPA-induced dyskinesias. Mov Disord 14 [Suppl 1]:4-8.
4. Benn CL, Farrell LA, Cha JH (2004) Neurotransmitter receptor analysis in transgenic mouse models. Methods Mol Biol 277:231-260.
5. Bibbiani F, Oh JD, Petzer JP, Castagnoli N Jr, Chen JF, Schwarzschild MA, Chase TN (2003) A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp Neurol 184:285-294.
6. 2A antagonism reverses levodopa-induced motor alterations in hemiparkinsonian rats. Synapse 46:251-257.
7. Brotchie JM (2005) Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov Disord 20:919-931.
8. Calon F, Birdi S, Rajput AH, Hornykiewicz O, Bedard PJ, Di Paolo T (2002) Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias. J Neuropathol Exp Neurol 61:186-196.
9. Calon F, Dridi M, Hornykiewicz O, Bedard PJ, Rajput AH, Di Paolo T (2004) Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain 127:1075-1084.
10. Chase TN (1998) Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology 50:S17-S25.
11. 2A adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 21:RC143(1-6).
12. Chen JF, Fredduzzi S, Bastia E, Yu L, Moratalla R, Ongini E, Schwarzschild MA (2003) Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease. Neurology 61:S74-S81.
13. 2A receptor heteromers. J Neurosci 26:2080-2087.
14. Dassesse D, Massie A, Ferrari R, Ledent C, Parmentier M, Arckens L, Zoli M, Schiffmann SN (2001) Functional striatal hypodopaminergic activity in mice lacking adenosine A(2A) receptors. J Neurochem 78:183-198.
15. Dragatsis I, Zeitlin S (2000) CaMKIIalpha-Cre transgene expression and recombination patterns in the mouse brain. Genesis 26:133-135.
16. Dragatis I, Levine MS, Zeitlin S (2000) Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet 26:300-306.
17. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K (2004) Levodopa and the progression of Parkinson's disease. N Engl J Med 351:2498-2508.
18. Fenu S, Pinna A, Ongini E, Morelli M (1997) Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. Eur J Pharmacol 321:143-147.
19. Ferre S, Fredholm BB, Morelli M, Popoli P, Fuxe K (1997) Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci 20:482-487.
20. Franklin K, Paxinos G (1997) The mouse brain in stereotaxic coordinates. San Diego: Academic.
21. 2A adenosine receptors. J Neurosci 22:1054-1062.
22. Fredholm BB, Cunha RA, Svenningsson P (2003) Pharmacology of adenosine A2A receptors and therapeutic applications. Curr Top Med Chem 3:413-426.
23. Grandas F, Galiano ML, Tabernero C (1999) Risk factors for levodopa-induced dyskinesias in Parkinson's disease. J Neurol 246:1127-1133.
24. Grondin R, Bedard PJ, Hadj Tahar A, Gregoire L, Mori A, Kase H (1999) Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology 52:1673-1677.
25. 2A receptor antagonist istradefylline in advanced PD. Neurology 61:297-303.
26. Jenner P (2000) Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments. J Neurol 247 [Suppl 2]:II43-II50.
27. Jenner P (2003) A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD. Neurology 61:S32-S38.
28. Jenner P (2005) Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease. Expert Opin Investig Drugs 14:729-738.
29. 2A receptors in normal and parkinsonian mice. J Neurosci 25:10414-10419.
30. 2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 43:507-513.
31. Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, Kuwana Y, Jenner P (2000) Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol 162:321-327.
32. Kase H (2001) New aspects of physiological and pathophysiological functions of adenosine A2A receptor in basal ganglia. Biosci Biotechnol Biochem 65:1447-1457.
33. Kase H, Aoyama S, Ichimura M, Ikeda K, Ishii A, Kanda T, Koga K, Koike N, Kurokawa M, Kuwana Y, Mori A, Nakamura J, Nonaka H, Ochi M, Saki M, Shimada J, Shindou T, Shiozaki S, Suzuki F, Takeda M, et al. (2003) Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease. Neurology 61:S97-S100.
34. Linazasoro G (2005) New ideas on the origin of L-DOPA-induced dyskinesias: age, genes and neural plasticity. Trends Pharmacol Sci 26:391-397.
35. Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA (2002) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 15:120-132.
36. Lundblad M, Vaudano E, Cenci MA (2003) Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of L-DOPA-induced dyskinesia. J Neurochem 84:1398-1410.
37. Lundblad M, Picconi B, Lindgren H, Cenci MA (2004) Amodel of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 16:110-123.
38. Morissette M, Dridi M, Calon F, Tahar AH, Meltzer LT, Bedard PJ, Di Paolo T (2006) Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin. Mov Disord 21:9-17.
39. Obeso JA, Olanow CW, Nutt JG (2000) Levodopa motor complications in Parkinson's disease. Trends Neurosci 23:S2-S7.
40. Okada M, Mizuno K, Kaneko S (1996) Adenosine A1 and A2 receptors modulate extracellular dopamine levels in rat striatum. Neurosci Lett 212:53-56.
41. Pinna A, di Chiara G, Wardas J, Morelli M (1996) Blockade of A2a adenosine receptors positively modulates turning behaviour and c-Fos expression induced by D1 agonists in dopamine-denervated rats. Eur J Neurosci 8:1176-1181.
42. Pinna A, Fenu S, Morelli M (2001) Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats. Synapse 39:233-238.
43. Quarta D, Ferre S, Solinas M, You ZB, Hockemeyer J, Popoli P, Goldberg SR (2004) Opposite modulatory roles for adenosine A1 and A2A receptors on glutamate and dopamine release in the shell of the nucleus accumbens. Effects of chronic caffeine exposure. J Neurochem 88:1151-1158.
44. 2A receptor knock-out mice. Soc Neurosci Abstr 31:230.19.
45. Rodrigues RJ, Alfaro TM, Rebola N, Oliveira CR, Cunha RA (2005) Colocalization and functional interaction between adenosine A(2A) and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum. J Neurochem 92:433-441.
46. Schiffmann SN, Jacobs O, Vanderhaeghen JJ (1991) Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J Neurochem 57:1062-1067.
47. Tomiyama M, Kimura T, Maeda T, Tanaka H, Kannari K, Baba M (2004) Upregulation of striatal adenosine A2A receptor mRNA in 6-hydroxydopamine- lesioned rats intermittently treated with L-DOPA. Synapse 52:218-222.
48. Weiss SM, Benwell K, Cliffe IA, Gillespie RJ, Knight AR, Lerpiniere J, Misra A, Pratt RM, Revell D, Upton R, Dourish CT (2003) Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease. Neurology 61:S101-S106.
49. Winkler C, Kirik D, Bjorklund A, Cenci MA (2002) L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 10:165-186.
50. Xu K, Bastia E, Schwarzschild M (2005) Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease. Pharmacol Ther 105:267-310.
51. Zeng BY, Pearce RK, MacKenzie GM, Jenner P (2000) Alterations in pre-proenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA. Eur J Neurosci 12:1096-1104.